Clinical Trial: Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Study Status: Completed
Recruit Status: RECRUITING
Condition: Locally Advanced Unresectable or Metastatic Esophageal Cancer
Study Type: INTERVENTIONAL
Official Title: A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors.
Brief Summary:
This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.
Read more